Sagimet Biosciences (SGMT) Profit After Tax (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Profit After Tax of -$10.8 million for Q1 2026, up 41.14% year-over-year from -$7.6 million in Q1 2025, and down 12.51% quarter-over-quarter from -$9.6 million in Q4 2025.
Sagimet Biosciences (SGMT) Profit After Tax (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Profit After Tax history runs 5 years deep, the most recent figure standing at -$10.8 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 41.14% year-over-year to -$10.8 million; the TTM figure through Mar 2026 stood at -$43.6 million (up 23.84% YoY), while the FY2025 annual figure was -$51.1 million, down 12.25% from the prior year.
- Profit After Tax for Q1 2026 stood at -$10.8 million, down from -$9.6 million in the prior quarter.
- The five-year high for Profit After Tax was -$6.4 million in Q3 2023, with the low at -$18.3 million in Q1 2025.
- The 5-year median for Profit After Tax is -$8.1 million (2023), against an average of -$9.8 million.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax sank 175.83% in 2025, then jumped 41.14% in 2026.
- Sagimet Biosciences' Profit After Tax stood at -$7.2 million in 2022, then dropped by 13.22% to -$8.2 million in 2023, then sank by 98.76% to -$16.2 million in 2024, then surged by 40.96% to -$9.6 million in 2025, then dropped by 12.51% to -$10.8 million in 2026.
- Business Quant data shows SGMT's Profit After Tax at -$10.8 million in Q1 2026, -$9.6 million in Q4 2025, and -$12.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | -14.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.04 Mn |
| Mar 31, 2026 | -10.76 Mn |
| Dec 31, 2025 | -9.57 Mn |
| Sep 30, 2025 | -12.87 Mn |
| Jun 30, 2025 | -10.39 Mn |
| Mar 31, 2025 | -18.29 Mn |
| Dec 31, 2024 | -16.20 Mn |
| Sep 30, 2024 | -14.62 Mn |
| Jun 30, 2024 | -8.12 Mn |
| Mar 31, 2024 | -6.63 Mn |
| Dec 31, 2023 | -8.15 Mn |
| Sep 30, 2023 | -6.35 Mn |
| Jun 30, 2023 | -6.79 Mn |
| Mar 31, 2023 | -6.59 Mn |
| Dec 31, 2022 | -7.20 Mn |
| Sep 30, 2022 | -7.47 Mn |
| Jun 30, 2022 | -7.10 Mn |